Alzheimer’s research is entering a new phase. For decades, the field has been shaped by the biology of amyloid plaques and tau tangles. Those remain central to how Alzheimer’s disease is defined and understood.Across four recent episodes of The Genetics Podcast, a broader picture emerges: the future of Alzheimer’s precision medicine will depend not only on identifying pathology, but on understanding timing, heterogeneity, genetics, cell biology, population diversity, and patient experience.
Taken together, conversations with Dr. Suzanne Schindler, Dr. Sarah Marzi, Dr. Paul Valdmanis, and Angela Bradshaw show a field moving from broad labels toward a more precise view of disease.
One of the clearest messages from Dr. Suzanne Schindler’s episode is that Alzheimer’s disease and dementia are often conflated, but they are not the same thing. Dementia describes a decline in memory and thinking that affects daily life. Alzheimer’s is one cause of dementia and is biologically defined by amyloid plaques and tau neurofibrillary tangles.
Many people with cognitive impairment have mixed pathologies, including vascular disease, TDP-43, alpha-synuclein, and other contributors alongside amyloid and tau. This complexity is one reason why diagnosis, prognosis, and treatment response can vary so widely between individuals.
For precision medicine, this means we need to understand not just whether Alzheimer’s pathology is present, but what else is happening in the brain and body.
Blood-based biomarkers are one of the most important shifts in the field. Dr. Schindler discusses p-tau217 as a marker that can reflect Alzheimer’s-related biology long before symptoms appear. In her work, biomarker trajectories may help estimate when someone became biomarker-positive and how close they may be to developing symptoms, although she is careful to note that these estimates are not yet precise enough for routine clinical use.
This is already highly relevant for clinical trials. If trials are short, enrolling people who are unlikely to progress during the study window makes it harder to measure whether a treatment works. Biomarkers could help identify participants at the right stage of disease, whether that means amyloid-positive, tau-positive, pre-symptomatic or already showing early cognitive changes.
Angela Bradshaw’s episode adds an important translational point: the science of biomarkers is advancing quickly, but the field still needs to understand how these tools perform across different populations and how they can be implemented responsibly in real-world clinical pathways.
APOE remains one of the strongest genetic risk factors for late-onset Alzheimer’s disease. Dr. Schindler explains that APOE ε4 appears to make people more likely to begin accumulating amyloid, while the relationship between APOE, tau, age, and sex remains an active area of research.
Dr. Paul Valdmanis’ episode shows how much more there is to uncover. His work uses long-read sequencing to investigate variation around the APOE locus, including a protective deletion found on African ancestry haplotypes. This variant appears to modify risk in a way that may have been missed without long-read sequencing and more diverse datasets.
That is a crucial point for the future of Alzheimer’s precision medicine. If discovery cohorts are not diverse, the field risks missing biology that could explain why risk differs across populations and could reveal new therapeutic strategies.
Dr. Sarah Marzi’s work highlights another major shift: Alzheimer’s cannot be understood only through amyloid and tau. Her research focuses on how genetic and environmental risk factors shape cell states, especially in microglia, the resident immune cells of the brain.
Microglia are increasingly important because Alzheimer’s genetic risk appears to be enriched in regulatory regions active in these cells. In Dr. Marzi’s APOE work, different APOE variants changed microglial behaviour, including motility, inflammatory signalling, and phagocytosis. Her broader postmortem brain work also points to lipid processing, immune responses, oligodendrocyte changes, myelination, and blood-brain barrier breakdown as part of the wider disease cascade.
This reveals that Alzheimer's is a long, multi-cellular process involving immune function, lipid metabolism, neuronal health, vascular integrity, and resilience.
The therapeutic landscape is also changing. Anti-amyloid therapies have shown that modifying Alzheimer’s biology is possible, especially earlier in disease. But the episodes make clear that amyloid clearance alone is unlikely to be the whole answer.
Dr. Schindler points to the potential for combined amyloid and tau approaches, while also noting the complexity of targeting inflammation and APOE biology. Dr. Marzi similarly suggests that future strategies may need to alter upstream causal events while also preserving function for longer, for example through synaptic or neuronal support.
The emerging model looks less like a single cure and more like stage-specific intervention: prevent or delay pathology where possible, slow progression once pathology is underway, and support cognition and function for as long as possible.
Angela Bradshaw’s episode is especially important because it brings the research conversation back to patients, families, and health systems. She emphasizes the importance of involving patients as the end users of research, whether the goal is better diagnosis, treatment, data sharing or care.
This is central to whether Alzheimer’s precision medicine succeeds. Biomarkers need to be communicated responsibly. Trials need to include representative populations. Clinical pathways need to be designed around real people, not idealized research participants. Healthcare systems need evidence that new tools can be implemented equitably and sustainably.
Across these four episodes, the state of Alzheimer’s research looks both exciting and complex.
The field is moving from late-stage clinical diagnosis to earlier biological detection, from broad categories to molecular and genetic subtypes, from single-pathway explanations to multi-cell, multi-pathology models. Finally, it is increasingly recognizing that discovery, clinical translation, and patient involvement have to develop together.
That is what makes this such an important moment for Alzheimer’s precision medicine. The field now has tools that can detect disease biology earlier, datasets that can reveal hidden genetic risk and protection, and cellular models that can explain mechanisms in more detail than ever before.
The challenge now is to connect those advances: to build more inclusive studies, design smarter trials, develop combination strategies and make sure the benefits reach the people and families affected by Alzheimer’s disease.